Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Biochem Biophys Res Commun. 2010 Nov 26;402(4):725-30. doi: 10.1016/j.bbrc.2010.10.093. Epub 2010 Oct 25.
Macrophage accumulation has been implicated in the pathogenesis of inflammatory glomerular disease. Monocyte chemoattractant protein-1 (MCP-1) plays a central role in recruiting monocytes to the glomeruli. Tumor necrosis factor-α (TNF-α) has been shown to induce MCP-1 expression in mesangial cells, although the precise mechanisms remain unclear. We previously demonstrated that RhoA and its effector, Rho-kinase (Rho-associated coiled-coil containing protein kinase, ROCK), are involved in the pathogenesis of diabetic nephropathy. However, its role in MCP-1 induction by TNF-α has not been elucidated. In the present study, we investigated whether the Rho/Rho-kinase signaling pathway regulates the TNF-α-mediated induction of MCP-1 in mesangial cells. Exposure of mouse mesangial cells (MES-13) to TNF-α resulted in an increase of MCP-1 expression (by RT-PCR) and secretion into the medium (by ELISA). Pull down and Western blot analysis revealed that TNF-α activated RhoA and Rho-kinase. Based on these observations, we speculated that the Rho/Rho-kinase signaling pathway may be involved in MCP-1 induction by TNF-α. In agreement with this concept, Y-27632, a specific Rho-kinase inhibitor, attenuated TNF-α-mediated induction of MCP-1. We demonstrated that Y-27632 inhibited TNF-α-mediated monocyte migration and attenuated TNF-α-mediated p38 MAPK activation. Based on these data we infer that Y-27632 inhibits TNF-α-induced MCP-1 expression, secretion and function through inhibition of Rho-kinase and p38 MAPK activity. Our study suggests that Rho/Rho-kinase is an important therapeutic target of monocyte recruitment and accumulation within the glomerulus in inflammatory renal disease.
巨噬细胞聚集与炎症性肾小球疾病的发病机制有关。单核细胞趋化蛋白-1(MCP-1)在募集单核细胞到肾小球中起核心作用。肿瘤坏死因子-α(TNF-α)已被证明可诱导肾小球系膜细胞表达 MCP-1,但确切机制尚不清楚。我们之前的研究表明,RhoA 及其效应物 Rho-激酶(Rho 相关卷曲螺旋蛋白激酶,ROCK)参与了糖尿病肾病的发病机制。然而,其在 TNF-α诱导的 MCP-1 表达中的作用尚未阐明。在本研究中,我们研究了 Rho/Rho-激酶信号通路是否调节 TNF-α介导的系膜细胞中 MCP-1 的诱导。TNF-α 暴露于小鼠系膜细胞(MES-13)导致 MCP-1 表达(通过 RT-PCR)和分泌到培养基中(通过 ELISA)增加。下拉和 Western blot 分析表明 TNF-α激活了 RhoA 和 Rho-激酶。基于这些观察结果,我们推测 Rho/Rho-激酶信号通路可能参与了 TNF-α诱导的 MCP-1。与这一概念一致,Rho-激酶特异性抑制剂 Y-27632 减弱了 TNF-α介导的 MCP-1 诱导。我们证明 Y-27632 抑制了 TNF-α介导的单核细胞迁移,并减弱了 TNF-α 介导的 p38 MAPK 激活。基于这些数据,我们推断 Y-27632 通过抑制 Rho-激酶和 p38 MAPK 活性来抑制 TNF-α 诱导的 MCP-1 表达、分泌和功能。我们的研究表明,Rho/Rho-激酶是炎症性肾脏疾病中肾小球内单核细胞募集和聚集的重要治疗靶点。